First-ever Winners of Prince William’s Earthshot Prize announced at star-studded London Awards Ceremony
The Earthshot Prize has tonight revealed the first-ever five Winners at a glittering ceremony held in London. Each Winner will receive £1million prize money and a global network of support to scale their cutting-edge environmental solutions to repair our planet.
The five Winners, which span the globe from Costa Rica to India, include transformative technologists, innovators, an entire country, and a pioneering city and were chosen for their ground-breaking solutions to the greatest environmental challenges facing our planet.
Earthshot Prize Founder and Prize Council Member Prince William said:
“Our five inspirational Winners show that everyone has a role to play in the global effort to repair our planet. We need businesses, leaders, innovators, and communities to take action. And, ultimately, we need all of us to demand that the solutions get the support they need. Because the success of our Winners is our collective, global Earthshot.”
Earthshot Prize Council Member Sir David Attenborough said:
“The natural world on which we entirely depend is declining at a rate faster than at any time since the end of the dinosaurs. We know where this story is heading and we must now write a different ending. This is what The Earthshot Prize was created to achieve. The 15 Earthshot Prize Finalists tonight build optimism by finding innovative and brilliant solutions to the world’s challenges, and they give us hope, which, we are told, springs eternal.”
The Earthshot Prize Winners for 2021 are:
- Protect and Restore Nature: The Republic of Costa Rica
- With an innovative policy paying citizens to protect the rainforests and restore local ecosystems, the people of Costa Rica and their Ministry for Environment have reversed decades of deforestation. Since the programme launched, Costa Rica’s forests have doubled in size, leading to a boom in ecotourism and contributing $4 billion to the economy
- Through winning The Earthshot Prize, Costa Rica will expand their work to protect the ocean and support the replication of their approach in other countries, especially in the Global South.
- Clean our Air: Takachar, India
- New Delhi-based Takachar has developed pioneering technology to help end the burning of agricultural waste, which causes severe air pollution. Their cheap, small-scale, portable technology attaches to tractors and converts crop residues into sellable products like fuel and fertilizer and helps reduce smoke emissions by up to 98%.
- By winning The Earthshot Prize, Takachar will expand its operations to more rural communities around the world with a goal to cut a billion tonnes of carbon dioxide a year.
- Revive our Oceans: Coral Vita, Bahamas
- Coral Vita’s innovative approach to coral farming of growing coral on land then replanting it in the ocean can grow coral up to 50 times faster than traditional methods and improves coral resilience to the impact of climate change.
- Winning The Earthshot Prize will accelerate Coral Vita’s goal to establish a global network of coral farms to grow a billion corals each year.
- Build a Waste-free World: The City of Milan Food Waste Hubs, Italy
- As the first major city to enforce a city-wide food waste policy, Milan’s Food Waste Hub programme recovers food from local supermarkets and restaurants and distributes it to citizens in need, recovering about 130 tonnes of food per year, an estimated 260,000 meals equivalent.
- Through winning The Earthshot Prize, the city of Milan’s model can be scaled to other cities.
- Fix our Climate: AEM Electrolyser, Thailand/Germany/Italy
- The AEM Electrolyser from Enapter turns renewable electricity into emission-free hydrogen gas with a technology that has been developed quicker and cheaper than ever before and can transform how we power our homes and buildings and fuel transport.
- Funding from The Earthshot Prize will help scale mass production, making it universally easy to buy and install AEM Electrolysers wherever activities have high energy demand.
The ceremony capped a 10-month global search with over 750 applications from around the world. 15 Finalists were chosen through a rigorous selection process, supported by an Expert Advisory Panel, for their potential to positively impact people and the natural world and their ability to help us reach our Earthshot goals.
The five Winners were selected by The Earthshot Prize Council, a diverse team of influential individuals which includes: HRH Prince William, Her Majesty Queen Rania Al Abdullah of Jordan, Sir David Attenborough, Dr Ngozi Okonjo-Iweala, Indra Nooyi, Shakira Mebarak, Christiana Figueres, Luisa Neubauer, Cate Blanchett, Yao Ming, Daniel Alves Da Silva, Ernest Gibson, Hindou Oumarou Ibrahim, Jack Ma, and Naoko Yamazaki.
The Winners were connected to the Awards Ceremony by global broadcast, where The Duke and Duchess of Cambridge were joined by Sir David Attenborough, Christiana Figueres, Dani Alves and a host of stars and performers including Ed Sheeran and Yemi Alade.
All 15 Finalists will receive tailored support from The Earthshot Prize Global Alliance, an unrivalled network of philanthropies, NGOs, and private sector businesses around the world who will help scale their solutions.
The Awards Ceremony concluded by revealing The Earthshot Prize will travel to the United States of America in 2022. Nominations for the 2022 Prize will open in January 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211017005030/en/
Contact information
For more information about The Earthshot Prize Winners, visit:
www.earthshotprize.org,
email Claire Straw:
TEPmedia@freuds.com,
download media pack here.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
